A

170.3802.83%
GA

George A. Scangos

Independent Director

Dr. George A. Scangos, Ph.D., serves as Independent Director of Voyager Therapeutics, Inc. since May 9, 2023. He serves as Venture Partner at Arch Venture Partners, L.P. He had been the Chief Executive Officer, Founding President (2016-2023) and served as a board member of Vir Biotechnology, Inc. since January 2017 until May 25, 2025 Under his leadership, Vir delivered life-saving therapies for Ebola and COVID-19 to millions of patients while also building a pipeline spanning five therapeutic areas and Director since January 2017 and served in an advisory role since April 03, 2023 until June 02, 2023. Dr. Scangos serves as Co-Founder & Director of Rezo Therapeutics Inc. and served its Board Chairperson. He served as the Chief Executive Officer of Biogen Idec Ltd. since July 2010 to December 2016. He served as the Chief Executive Officer and Director of Biogen Inc. from July 2010 to January 2017. He served as the President and Chief Executive Officer of Exelixis, Inc., a holding company of X-ceptor Therapeutics Inc. from October 1996 to July 2010. He served as the President of Biotechnology of Bayer Corporation from September 1993 to October 1996 and was responsible for many employees in research and development, business development, process development, manufacturing, engineering and quality assurance. He worked at Bayer Corporation. He joined Bayer in 1987 as a Staff Scientist. At Bayer, he served in several positions, including Senior Vice President of Research and Development for Bayer's Pharmaceutical Division and then President of Bayer Biotechnology From 1996 to July 2010. He has experience in the biotechnology and pharmaceutical industries. He served as the Chairman of the California Healthcare Institute in 2010. He served as the Chairman of Anadys Pharmaceuticals Inc. from December 31, 2005 to 2010. He served as a former chair of PhRMA. He was also a member of the Board of Directors of the Global Alliance for TB Drug Development. He serves as the Vice Chairman of California Healthcare Institute (CHI) and California Life Sciences Association. He serves as Director of Octave Bioscience, Inc. He was a Director at Exelixis, Inc. since October 1996 until May 20, 2020. He served as a Director of Decibel Therapeutics, Inc. since January 18, 2017 until June 2020 and serves as Independent Director at Agilent Technologies, Inc. since January 2011 and Biogen Idec Ltd. since July 2010. He serves as a Director of BayBio, Symphony Evolution, Inc. and Foundation Sante. He serves as a Member of Advisory Board at QB3. He served as an Independent Director at Anadys Pharmaceuticals Inc. since October 2003. He served as a Non-Executive Director at Entelos, Inc. since September 1997. He served as a Director at Bay Area Bioscience Association. He served as a Director of Biogen Inc. from July 2010 to January 6, 2015. He served as a Director at Onyx Pharmaceuticals, Inc. from June 2000 to March 2005. He serves as an Adjunct Professor of Biology at Johns Hopkins University. He was a Professor of Biology at Johns Hopkins University. He serves as a Member of the Boards of Trustees of the Boston Museum of Science and the Biomedical Science Careers Program and a Member of the National Board of Visitors of the University of California, Davis School of Medicine. He serves on the Board of Visitors at the University of California, San Francisco School of Pharmacy, the Board of Overseers at the University of California, Davis Medical School. He served as the Chairman of the Board of Directors at Pharmaceutical Research and Manufacturers of America (PhRMA) from March of 2016 to January of 2017. He was named “Businessperson of the Year” by Fortune in 2014 and 2015 and also named one of “The Best Performing CEOs in the World” by Harvard Business Review for three consecutive years (2014 – 2016). He also serves on the boards of Agilent Technologies, Inc., Voyager Therapeutics, Inc., Octave Bioscience, Rezo Therapeutics and Life Sciences Cares. He was a Jane Coffin Childs Postdoctoral Fellow in the laboratory of Frank Ruddle at Yale University. He served as a Member of The Board of the Global Alliance for TB Drug Development since 2006 until 2010. He serves on the Board of Trustees of Cornell University. Dr. Scangos has several years of experience building and leading biopharmaceutical companies. He holds a B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.

Positions